Yusoff K, Nesbit M, McCartney H, Emmerson P T, Samson A C
Department of Biochemistry and Genetics, Medical School, University of Newcastle upon Tyne, U.K.
Virus Res. 1988 Nov;11(4):319-33. doi: 10.1016/0168-1702(88)90005-6.
Nine neutralizing monoclonal antibodies (MAbs), each of which react with the haemagglutinin-neuraminidase (HN) glycoprotein of the Beaudette C strain of Newcastle disease virus (NDV), have been used in competitive binding assays to delineate three non-overlapping antigenic sites A, B and C. Epitopes within these sites have been identified on the basis of cross-reactivity of MAb-resistant mutants against the panel of MAbs, determined by plaque assays and Western blotting. Site A contains three non-overlapping epitopes (A1, A2 and A3). A1 is the only linear epitope; all remaining epitopes are conformational. MAbs which react with epitopes A2 and A3 inhibit neuraminidase activity (NA) when assayed with neuraminlactose. Site B contains three partially overlapping epitopes (B1, B2 and B3) and site C is represented by a single epitope (C1). HN gene sequence analysis of MAb-resistant mutants showed that they each had only single amino acid substitutions which range from amino acid residues 347-460 for site A, 284-325 for site B, and at 481 for the C1 epitope. The apparent molecular mass of the HN glycoprotein of one mutant was increased from 72 to 75 kDa. This correlates well with the creation of an additional potential glycosylation site in this mutant from Asn-Ser-Pro(325) to Asn-Ser-Ser(325).
九种中和单克隆抗体(MAb),每种都与新城疫病毒(NDV)博德特C株的血凝素神经氨酸酶(HN)糖蛋白发生反应,已用于竞争性结合试验,以确定三个不重叠的抗原位点A、B和C。这些位点内的表位已根据抗MAb突变体对该组MAb的交叉反应性确定,通过噬斑试验和蛋白质印迹法进行测定。位点A包含三个不重叠的表位(A1、A2和A3)。A1是唯一的线性表位;其余所有表位都是构象性的。与表位A2和A3反应的单克隆抗体在用神经氨酸乳糖测定时会抑制神经氨酸酶活性(NA)。位点B包含三个部分重叠的表位(B1、B2和B3),位点C由单个表位(C1)代表。对单克隆抗体抗性突变体的HN基因序列分析表明,它们各自只有单个氨基酸取代,位点A的氨基酸残基范围为347 - 460,位点B为284 - 325,C1表位为481。一种突变体的HN糖蛋白的表观分子量从72 kDa增加到75 kDa。这与该突变体中从Asn - Ser - Pro(325)到Asn - Ser - Ser(325)产生一个额外的潜在糖基化位点密切相关。